Does Molina Cover Wegovy?

Disclosure: Some links on this page are affiliate links. If you use them, we may earn a commission at no extra cost to you. It never changes what we tell you — our verdicts come from the plan documents, not from payouts.

By The RX Index Editorial Team — the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

Last verified: August 20, 2026

This is information, not medical advice. Only a licensed clinician can decide whether Wegovy is right for you.

Molina covers Wegovy through four possible paths, and which one is open depends on your state and plan type — not on the word “Molina.” For weight loss alone, most Molina members are excluded. But Mississippi has a confirmed adult and teen prior-authorization path, Michigan has a much narrower adult path tied to avoiding bariatric surgery, Wisconsin has a teen path, and Molina publishes separate medical criteria for cardiovascular risk reduction and MASH. If none applies, the standard Wegovy pen costs $349 a month through the manufacturer self-pay offer — a price your Medicaid or Medicare card does not disqualify you from.

That last part surprises almost everyone. We'll get to it, because it's the single most useful thing on this page.

Here's why you've been getting mixed answers. We read both of Molina's current Wegovy policy documents end to end. One of them tells Molina's own reviewers, in capital letters, to go check your state and your plan type before answering. So when Molina's website won't give you a yes or no, it isn't dodging you. The question genuinely has more than one answer — and nobody has done the lookup for you.

We did. Every current Molina Medicaid state, both national policies, the current FDA label, the appeal rules, and the current manufacturer prices are below.

Is this page for you?

Does Molina cover Wegovy? The 30-second answer by plan type

One line to take with you: the medicine is the same. The reason it's prescribed is what your plan is actually paying for or refusing.

### Not sure which lane you're in? Five questions — your card, your state, why it's prescribed, your age, and whether you've started. You get the exact Molina policy number your doctor's office needs, plus a printable request sheet. Find your Molina path in 60 seconds → Free. No signup. No member ID.

Your situation changes the answer

The right GLP-1 provider isn't the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path (injection or oral), and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose.

### 📋 What we actually verified We read Molina's current Medicaid Wegovy policy C27635-A and Molina's current Marketplace Wegovy policy C27682-A, both effective May 30, 2026, from first page to last. We checked the current FDA label for the standard injection, tablets, and Wegovy HD. We pulled Molina's corporate entity list dated January 30, 2026. We checked every current Molina Medicaid state, then read the official Mississippi, Michigan, Wisconsin, California, Massachusetts, Illinois, Kentucky, South Carolina, Utah, and Washington materials that give the clearest current answers. We checked Novo Nordisk's current prices and written eligibility rules. We checked the federal Bridge and Medicaid appeal rules against CMS and the regulations themselves. What we could not verify: a public adult obesity-only Wegovy route in every remaining Molina state, or the full approval criteria inside Molina's California and New Mexico Marketplace weight-management policies. We name those documents below so your doctor's office can request them by number. “Not publicly verified” is not the same as “denied.” Prices and plan rules change. Re-check before you act.

Why won't anyone give you a straight answer?

Because a straight answer would be wrong. Molina writes national policies, but those policies point back to your state and your plan before deciding anything. On the Medicaid side, federal law lets each state choose whether to cover weight-loss drugs at all — and most states have chosen not to.

Here's the sentence, straight out of Molina's own Medicaid Wegovy policy. It's addressed to Molina's own reviewers, and it's in capital letters in the original document:

"PLEASE FIRST REFER TO STATE AND LINE OF BUSINESS EXPLANATION OF BENEFITS TO DETERMINE IF WEIGHT LOSS IS A COVERED BENEFIT." — Molina Healthcare, policy C27635-A, effective May 30, 2026

Read that again. Molina's own reviewer, holding Molina's own policy, is told to go look somewhere else first.

That's not a loophole. That's how Medicaid works. Section 1927 of the Social Security Act lets a state leave certain drug categories off its list, and agents used for anorexia, weight loss, or weight gain are among them. Some states keep a path. Most do not. Molina must still apply your state benefit, your plan document, and the current drug list.

So your real answer is a combination of five things:

Your plan type × your state × the reason it's prescribed × which Wegovy product × your plan's current drug list.

Change any one of those five and the answer can flip.

You're not imagining the runaround. Here's how Molina members describe it in public forums:

"I get mixed results online saying that it does cover, while other sources say it's excluded."

"I am tossed back and forth and cannot get any straight answers."

(Public member comments from r/Wegovy and r/medicare. We're quoting them because they describe the problem accurately — not as proof of what any plan covers.)

A small accuracy note, so you know we actually opened the file. Molina's policy cites “Social Security 1927(d)(3)(A).” The excludable-drug list it quotes is at §1927(d)(2). That subsection mismatch does not change your answer, but it is one more reason to read the source instead of copying a policy number from another page.

What Molina actually requires to approve Wegovy: the four doors

Molina's Medicaid policy lists exactly two medical doors — prior heart attack, stroke, or peripheral artery disease; and MASH liver disease at fibrosis stage F2 or F3. Both require a specialist's involvement. Weight loss is a third door that only opens if your state and plan keep it open, and a fourth door exists through EPSDT for anyone under 21. Knowing which door you're walking through changes what your doctor has to write down.

Here they are in one place.

Door 1 — Weight loss

Open only if your state and plan kept it. Skip to the state table below.

Door 2 — You've had a heart attack, a stroke, or artery disease in your legs

All of these have to be true:

Read requirement 4 twice. If you have type 2 diabetes, this door closes under Molina's Wegovy cardiovascular criteria — the plan may route the request toward a diabetes GLP-1 instead. And requirement 1 is narrower than most people assume. Heart failure alone doesn't qualify. High blood pressure alone doesn't qualify. A strong family history doesn't qualify. It has to be a heart attack, a stroke, or symptomatic artery disease in your legs.

Door 3 — MASH (a liver disease, formerly called NASH)

Door 4 — If you're under 21

This one isn't in Molina's adult policy criteria. It comes from federal Medicaid law, and it can require an individual medical-necessity review even when the ordinary adult benefit excludes weight-loss drugs. Full section below.

### 🔑 Can't get a specialist appointment? Molina's own policy has an answer. Doors 2 and 3 both require a cardiologist or a liver specialist. That's the single biggest practical blocker, and it stops a lot of people who would otherwise qualify. Molina's policy tells reviewers to give special consideration when a specialist is unavailable nearby, appointments are not timely, or the requesting clinician is actively managing the member's cardiovascular or metabolic care. Translation: if the nearest cardiologist is four months out, your regular doctor should say that in writing, inside the request. Not on the phone. In the paperwork. That one sentence is the most useful thing on this page for anyone walking through Door 2 or Door 3.

One more rule that trips people up. Molina's current policy separates the three products. For the standard injection, 1.7 mg or 2.4 mg weekly are maintenance doses; 0.25, 0.5, and 1 mg are initiation and escalation doses. For the tablet, 25 mg daily is the maintenance dose; 1.5, 4, and 9 mg are escalation doses. Wegovy HD is a 7.2 mg weekly adult weight-management product after 2.4 mg is tolerated and more weight reduction is indicated.

The policy sets an age floor of 18 and older. The cardiovascular door applies to the standard injection and tablets. The MASH door applies to the standard injection only. Wegovy HD sits only in the adult weight-management lane.

### Does one of these doors describe you? We'll build the request sheet for your door — the policy number, the criteria in your doctor's language, and the specialist wording if you need it. Get the printable request sheet → One page. Free. Hand it to your prescriber.

Molina Marketplace: the exclusion is bigger than almost anyone realizes

On Molina Marketplace plans, weight-loss drugs are a benefit exclusion in most states — and Molina's 2026 policy says that in those states, the exclusion applies to every Wegovy use, including heart-attack prevention and MASH. California and New Mexico are the only two exceptions Molina names.

This is the finding that changes the most answers, and it is easy to miss because it sits inside the plan-exclusion language.

Molina's Marketplace policy C27682-A, effective May 30, 2026, says Wegovy injection and tablets are “considered a benefit exclusion for all indications” in states where weight-loss drugs are excluded. The policy then names weight management, repeat cardiovascular-event risk reduction, and MASH among the blocked uses.

Why that matters so much

An FDA approval for a medical use does not automatically defeat a benefit exclusion written into your plan contract.

Molina's Marketplace policy says the exclusion swallows the medical uses too.

Which creates a backwards result nobody expects. A Molina Medicaid member who survived a heart attack may have a written criteria path if the state benefit, formulary, and prior authorization line up. A Molina Marketplace member, in the same state, with the same heart attack, may not if the Evidence of Coverage excludes weight-loss drugs. People assume commercial coverage always beats Medicaid coverage. On this drug, at this company, it can be the other way around.

If you're a Marketplace member reading that with a sinking feeling

Three things, in order:

1. Get your Evidence of Coverage — the full benefit booklet, not the summary. Search it for “weight loss,” “weight reduction,” and “anti-obesity.” The exclusion either is or isn't in there. Molina's policy defers to that document.
2. Ask for the answer in writing. A benefit exclusion and “not on the drug list” are different problems with different fixes. Ask Molina to identify which one applies and whether your plan allows a formulary or medical-necessity exception.
3. Read the cost section below. Marketplace members have one advantage Medicaid and Medicare members don't, and it can save real money.

California and New Mexico Marketplace: the two exceptions

Molina's policy says these two states use separate weight-management rules:

• California Marketplace — state language allows an exception when treatment is medically necessary for morbid obesity. A plan may require participation in a comprehensive weight-loss program if it covers one. Molina routes requests to Weight Management Therapy CA MMKP C28425-A.
• New Mexico Marketplace — state language covers prescription drugs medically necessary for obesity and morbid obesity while allowing an exclusion for ordinary weight reduction outside that exception. Molina routes requests to Weight Management Therapy NM MMKP C29220-A.

Be honest with yourself about what that means. These are conditional doors, not open ones. “Medically necessary for morbid obesity” is a bar, and Molina decides whether your record clears it. But it is a door, and in most states there isn't one.

Ask your doctor's office to request the policy by number. Give them “C28425-A” or “C29220-A.” Naming a document by its number gets a different response than asking a general question.

Does your state's Molina Medicaid cover Wegovy?

Molina runs Medicaid plans in 20 states, and Medicaid drug rules are set state by state — so “does Molina Medicaid cover Wegovy” has 20 different state answers before plan details enter the picture. The useful question is even narrower: does the current Molina Medicaid benefit have an adult Wegovy path when the drug is used for weight management?

First, the number you'll see everywhere, and what it actually means

KFF counted 13 state Medicaid fee-for-service programs covering GLP-1s for obesity as of January 2026.

That is not a Molina answer. Fee-for-service is the state's own drug program. Molina is managed care. The two often follow the same benefit, but not always. A state can also cover a weight-loss drug that is not a GLP-1.

This is where broad national lists go wrong. Texas, for example, reported coverage of a weight-loss drug but not a GLP-1 for obesity. A Texas Wegovy PA form proves a review process exists for some uses. It does not prove adult weight-loss-only Wegovy is a covered benefit.

The Molina state picture, as of August 2026

We're labeling these honestly. “Confirmed” means an official state or Molina document gives a direct answer. “No open route verified” means the public sources reviewed did not support a yes. It does not turn a public-information gap into a denial. Ask Molina to identify the controlling benefit document and answer in writing.

Virginia is not in the table because Molina's Virginia Medicaid plan ended June 30, 2025. Nevada is in the table because Molina's contract began January 1, 2026. Old coverage pages that still list Virginia and omit Nevada are using an outdated footprint.

Puerto Rico is not folded into this state table. Molina has a Puerto Rico legal entity, but this review did not find current public plan material that would support importing the mainland state answers into Puerto Rico's Medicaid rules.

The headline nobody has assembled

Mississippi is the only current Molina state where this review found a clearly published, normal adult Wegovy weight-management PA path. Michigan's surviving adult path is tied to avoiding bariatric surgery. Wisconsin's obesity path is for ages 12–17. Several other Molina states publish direct exclusions, while the rest require a plan-specific answer.

If your coverage stopped this year, you did nothing wrong. Your doctor did nothing wrong. The rule may have changed underneath you.

Four states worth spelling out

Mississippi. For an adult, the current state criteria allow a Wegovy request with a BMI of 30 or higher, or a BMI from 27 through 29 plus a qualifying weight-related condition. Ages 12 through 17 have separate criteria. A treatment plan and prior authorization are still required.

Michigan. Effective January 1, 2026, Michigan Medicaid kept a route, but it is not a normal BMI-based obesity benefit. The official letter requires morbid obesity, failure of all clinically appropriate interventions — including preferred anti-obesity agents — and use specifically to avoid bariatric surgery. The letter does not publish a BMI 40 rule.

Michigan also honored existing approvals only for the remaining six months authorized. If your Wegovy quietly stopped when that authorization expired, that's the mechanism — and it matters for your appeal rights. See the continuation trap below.

Wisconsin. The current criteria split by age and indication. The Wegovy injection has a weight-management path for ages 12 through 17. Adult routes are listed for cardiovascular risk reduction and MASH, and the tablet is listed for adult cardiovascular risk reduction. A page that simply colors Wisconsin green for “Wegovy weight loss” misses the adult-versus-teen split.

California. Medi-Cal's January 1, 2026 change closed adult coverage when GLP-1 drugs are used for weight loss or weight-related conditions. It did not erase every other FDA-approved indication. California says other uses can still be reviewed case by case, and under-21 requests remain subject to EPSDT medical-necessity review.

If your California claim says the product is not covered, get the exact written reason. A weight-use exclusion, a non-formulary product, and a diagnosis mismatch are different problems. Do not build an appeal around a pharmacy reject-code guess.

If you're under 21, a different federal rule applies

Federal Medicaid law requires states to arrange medically necessary Medicaid-coverable treatment for people under 21 when it is needed to correct or improve a condition — even when the ordinary adult state plan does not cover the same service. The rule is called EPSDT, and a plan cannot answer an under-21 request by simply saying “we don't cover weight-loss drugs.” It has to make an individual medical-necessity decision and explain a denial.

EPSDT stands for Early and Periodic Screening, Diagnostic and Treatment. It's one of the strongest rights in Medicaid and almost nobody knows about it.

Here's what it means in practice:

• A state's adult weight-loss exclusion does not automatically decide an under-21 request.
• The plan must review whether the medication is medically necessary for that specific young person and is a Medicaid-coverable service.
• A denial has to explain the reason and the appeal rights — not just point at the adult exclusion list.
• Required review does not mean automatic approval. Prior authorization, clinical records, FDA labeling, and medical-necessity evidence still matter.

California confirmed this in its own 2026 coverage-change materials: under-21 requests may still be reviewed for medical necessity under EPSDT even after the adult weight-use exclusion took effect.

The age gap worth flagging to your doctor

Molina's current Medicaid Wegovy policy sets an age floor of 18 and older. The FDA label covers the standard Wegovy injection for obesity beginning at age 12. Wegovy tablets and Wegovy HD are adult-only.

Those aren't the same numbers, and the difference matters:

• Age 12–17: the standard injection is FDA-approved for obesity, but Molina's national adult policy does not supply the route. Use an EPSDT medical-necessity request plus any state pediatric criteria. Mississippi and Wisconsin publish separate teen paths.
• Age 18–20: Molina's adult criteria may apply, and EPSDT rights still apply because the member is under 21.

What to say: “I'm requesting an individual medical-necessity review under EPSDT. Please identify the exact clinical or benefit reason in writing if you deny it.”

### Under 21, or requesting for your child? We'll build the EPSDT request language and the documentation list, plus what to do if the first answer is a flat exclusion notice. Get the under-21 request sheet →

Does Molina Medicare cover Wegovy?

Medicare Part D cannot cover Wegovy for weight loss alone — that's federal law, not a Molina decision. It may cover Wegovy for an FDA-approved cardiovascular or MASH use if the exact product is on your Molina formulary or approved by exception. And since July 1, 2026, there's a separate federal program that offers eligible Medicare members covered GLP-1 drugs at $50 a month for weight management, outside your plan entirely.

The two lanes

Lane 1 — Part D, for a covered medical reason. The standard Wegovy injection or tablet may go through Part D for cardiovascular risk reduction. The standard injection may go through Part D for MASH. Check the exact formulary, submit prior authorization, and request an exception if the product is not listed.

Lane 2 — the Medicare GLP-1 Bridge, for weight loss. A federal program running July 1, 2026 through December 31, 2027. Flat $50 per monthly supply. It runs outside your Part D plan — Molina doesn't have to opt in, and Molina isn't the one paying.

Who qualifies for the Bridge

A prescriber must attest that the drug is being used for weight management with ongoing nutrition and physical-activity changes, and that the adult meets one of these paths:

Five things about the Bridge that catch people

1. You do not need your Part D plan to deny you first. Your prescriber sends the prescription to the pharmacy. The pharmacy submits the Bridge claim. That claim creates the record needed to start the Bridge prior authorization. If the PA is sent before the pharmacy claim, CMS says it can return a “patient not found” error.

2. The 2026 fill trap. If you filled Zepbound, Mounjaro, Foundayo, Rybelsus, Ozempic, Wegovy, Saxenda, Victoza, or Trulicity through Part D at any point in 2026, CMS says you are not eligible for the Bridge in 2026. CMS has not set the 2027 lookback rule.

3. Three diagnoses send you back to Part D. The Bridge is not available if you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH with F2–F3 fibrosis. CMS sends those uses to Part D even when the Part D plan does not cover the GLP-1 you requested.

4. There's no separate Bridge appeal. If a Bridge request is denied, your prescriber can correct and resubmit with better information — but there is no separate appeal process for the Bridge itself. Your normal Part D appeal rights are separate and still apply to Part D decisions.

5. The $50 does not count toward your Part D out-of-pocket total. The Bridge operates outside Part D.

Full details: our Medicare GLP-1 Bridge guide →

You might be a Molina member and not know it

Molina operates under several other legal names and brands. Senior Whole Health in Massachusetts and New York, ConnectiCare in Connecticut, and Central Health Plan of California are all listed as Molina affiliated companies.

This comes straight from Molina's own corporate document, the Affiliated Health Plans List as of January 30, 2026. Molina names every legal entity under its umbrella, and several of them don't have “Molina” on the card:

• Senior Whole Health, LLC (Massachusetts)
• Senior Whole Health of New York, Inc.
• ConnectiCare, Inc., ConnectiCare Insurance Company, and ConnectiCare Benefits (Connecticut)
• Central Health Plan of California, Inc.
• Molina Healthcare of Puerto Rico, Inc.

Why this matters to you: if one of those names is on your card, Molina's policy library is a useful place to look. But common ownership does not prove that one national Molina document controls every product. Your exact plan's Evidence of Coverage, drug list, state rules, and line of business still decide the final answer.

When you call, use the exact name on the card and ask whether Molina policy C27635-A or C27682-A is being used in the review — and what member document controls if it is not.

Careful: a prior authorization form does not mean you're covered

A plan can publish a prior authorization form for a drug that your specific plan still excludes. The form proves a review process exists. It does not prove your intended use is a covered benefit. This is the single most common way people get bad information about Molina and Wegovy.

The order matters:

In Texas, for example, Molina publishes a real Wegovy prior-authorization addendum inside its Medicaid and CHIP criteria guide. It names records a prescriber may need to send — clinical notes, lab work, medication history, and more.

That form is real. It proves you can submit a request for a use reviewed under that guide. It does not prove Texas Molina Medicaid pays for Wegovy for adult weight loss. Those are two different facts, and the gap between them is where people lose months.

How to tell them apart in one phone call: don't ask “does Molina cover Wegovy?” Ask this instead:

“Is Wegovy [standard injection / tablet / HD] a covered benefit under my exact plan for [weight management / cardiovascular risk reduction / MASH], or is that use a benefit exclusion? If it is covered, is the product on the formulary, and what prior authorization criteria apply?”

Covered-with-paperwork and excluded-entirely feel the same at the pharmacy counter. They are completely different problems.

The pen, the pill, and Wegovy HD are not the same

Don't assume all three Wegovy products have the same coverage status or the same approved uses. Molina's current policy names the standard injection, Wegovy tablets, and Wegovy HD separately.

This has four practical consequences:

1. Different products, different codes, different formulary placement. Your plan can list one and not another.
2. If your request is for MASH, it has to be the standard injection. A tablet or HD request for MASH is asking for a use the label doesn't cover.
3. If your request is for cardiovascular risk reduction, it has to be the standard injection or tablet. Wegovy HD is not approved for that use.
4. Coverage-checking tools don't all cover all three. Ro's free insurance checker, for example, currently checks the Wegovy pen — not the Wegovy pill.

Say the exact product when you call. Not “Wegovy.” Say: “I'm asking about Wegovy [standard pen / tablets / HD], at [dose], prescribed for [reason].”

Molina said no. Here's exactly how to appeal.

For a Molina Medicaid denial, you have 60 calendar days from the notice to file a plan appeal, and federal rules allow an oral or written appeal. Molina generally must decide within 30 days, or within 72 hours for an expedited appeal. If Molina denies again, your state sets the State Fair Hearing deadline somewhere from 90 to 120 days after Molina's resolution notice. Read your notice for the exact number.

Federal Medicaid managed-care rules set the floor, but your state can add protections and choose the fair-hearing filing window within that federal range.

Ask for expedited review whenever the normal wait could seriously harm your life, health, or ability to regain maximum function. Say why in concrete terms and ask your clinician to support it.

The continuation trap — read this before your approval expires

You can ask Molina to keep paying for a previously authorized Medicaid service while you appeal. But federal rule 42 CFR 438.420 only allows that when the appeal is about a termination, suspension, or reduction of a previously authorized service, the original authorization has not expired, and the continuation request is timely.

The timing rule is the later of:

• 10 calendar days after Molina sends the adverse-benefit notice, or
• the effective date of the proposed action.

Read the authorization line again.

If your approval is cut off mid-term, you may be able to keep the medication while you fight. If the approval simply expires, the federal continuation rule does not extend the expired authorization. There's nothing left to continue.

That's why Michigan's six-month transition matters. Existing approvals were honored for the remaining authorized period, then allowed to expire. A person who waits until after expiration may still appeal a denial, but the continuation protection is a different question.

What to do with this: if you're on Wegovy through Molina right now and your state's rules are changing, find your notice date, proposed stop date, and authorization end date today. Those dates decide whether continued benefits are still available.

What to put in the appeal

A strong appeal answers the reason Molina actually gave you. Attach:

1. The denial notice and the exact reason code or sentence.
2. The exact product and FDA-approved use being requested.
3. The Molina policy number, state rule, formulary page, or Evidence of Coverage language that supports the path.
4. Chart notes proving every criterion — BMI, diagnosis, prior events, fibrosis stage, prior drugs, counseling, treatment goals, and specialist input when required.
5. A short clinician letter that explains why the record meets the criteria and why delay may cause harm.
6. A clear request for standard or expedited review and, when eligible, continued benefits.

Do not send a five-page story that never answers the denial reason. Make the reviewer able to check every box without hunting.

How long Molina actually took in one government audit

Set your expectations with a real number, not a promise.

California's Department of Health Care Services audited Molina Healthcare of California for the 2023–24 audit period. The plan standard reviewed in that audit required routine medical prior authorizations within five working days. For 15 of 26 sampled authorizations, Molina decided one to three working days late.

That was a sample of routine medical prior authorizations, not a Wegovy approval-time study and not a universal Molina deadline. It still tells you two useful things: do not plan around the fastest possible answer, and keep every submission timestamp.

The same audit reviewed 22 denied prior-authorization appeals, and Molina overturned and approved all 22. That does not predict your case. It does prove that a first denial is not always the last word.

California members: you may have a second tool

Molina of California is regulated by the Department of Managed Health Care. Its free Independent Medical Review can send a medical-necessity dispute to outside clinical reviewers, and the health plan must follow the decision.

DMHC reported that about 72% of Independent Medical Reviews in its statewide data resulted in the member receiving the requested service or treatment. That number covers California-regulated plans broadly — it is not a Molina-only or Wegovy-only success rate.

Free. Confidential. Help is available in all languages. 1-888-466-2219 or use the DMHC Help Center.

What a real denial looks like

This is a public government record, not a testimonial we collected — and it teaches the heart-attack rule better than any explanation could.

In a Massachusetts Board of Hearings appeal, case 2514230, a Medicaid member's records showed her ejection fraction improved from 20–25% to 54% while taking Wegovy with standard heart therapy, along with real weight loss. Her physician wrote that continuing Wegovy was necessary for cardiovascular risk reduction.

She was denied anyway. Her state had stopped covering Wegovy for obesity, and her records showed no prior heart attack, stroke, or peripheral artery disease.

That's the rule, in a real person's file. Improvement doesn't satisfy a list that requires a specific prior event. Heart failure alone isn't the same as a prior heart attack, stroke, or symptomatic peripheral artery disease.

(A MassHealth case, not a Molina case. It is here to show why the diagnosis written in the record has to match the actual criteria.)

### Got a denial letter? Tell us what it says and we'll tell you whether it's a fixable paperwork problem or a true plan exclusion — plus the appeal script, the expedited-review request, and how to ask for continued benefits. Decode my Molina denial → Free. Takes about two minutes.

What Wegovy costs if Molina won't pay

The standard Wegovy pen costs $349 a month through Novo Nordisk's self-pay offer, or $199 for each of the first two starter fills for an eligible new patient — compared with a current list price of $1,349.02. And here's the part almost every page gets backwards: being on Medicaid or Medicare does not disqualify you from the manufacturer self-pay price.

This is the most useful thing on this page, so let's do it properly.

Cash price and copay card are two different programs

NovoCare's current terms say people enrolled in government-funded medical or prescription programs “are able to pay the self-pay price.”

Your Medicaid or Medicare card does not lock you out of the cash price.

What you cannot use is Novo's commercial copay savings offer. Its terms exclude Medicaid, Medicare, VA, DoD, TRICARE, and similar government programs. A copay offer and a cash price are two different things, and only one of them is off-limits.

Current prices — verified August 20, 2026

Re-check before you commit. Novo can change these at any time, and two prices above have end dates.

The math that saves Marketplace members real money

Here's a mistake we see constantly, and one subtraction fixes it.

If you have a Molina Marketplace plan, Novo treats qualifying exchange coverage as commercial insurance. That gives you two different routes:

• If Molina covers Wegovy: the commercial copay offer can lower your covered cost, with a maximum savings of $100 for a one-month fill.
• If Molina excludes Wegovy: the covered-drug copay offer is not the route. Process the manufacturer not-covered/self-pay offer outside insurance instead.

So when the plan excludes the drug:

Current list price: $1,349.02 Manufacturer self-pay price: $349 Difference: $1,000.02 per month

The copay route is the wrong tool when the plan excludes the drug. Use the manufacturer self-pay route. The saving comes from choosing the right program, not subtracting $100 from a rejected insurance claim.

The honest counterweight

The self-pay offer operates outside insurance. Money you spend does not count toward your deductible or plan out-of-pocket limit, and Novo's terms say it cannot be submitted for insurer reimbursement.

Also worth knowing: if you have both commercial and government coverage, Novo counts you as a government-insurance patient for the commercial offer.

Hand this to your prescriber

If you already have a Wegovy prescription, this is what your doctor's office needs to send it to the manufacturer's own pharmacy:

NovoCare Pharmacy 2400 Sand Lake Rd, Ste. 200B, Orlando, FL 32809 NPI 1710671854 · NCPDP 5758074 Fax: 1-833-947-0246 · Phone: 1-833-949-5527

No membership. No telehealth fee. We earn nothing when you use this, and for a lot of people reading this page it's the right answer.

Before you reach for your wallet

If you're on Molina Medicaid, don't skip the free steps. In order:

1. Is a state weight-management path, the cardiovascular door, the MASH door, or EPSDT open to you?
2. Is your appeal window still open? Usually 60 days for a Medicaid plan appeal.
3. Then consider paying cash.

Self-pay should be your backup, not your opening move.

Which providers actually work with Molina?

The real covered path is a clinician who participates in your exact Molina network, writes the prescription, submits the prior authorization, and sends it to a network pharmacy. That may be your primary care doctor, an endocrinologist, an obesity-medicine clinician, a cardiologist, a liver specialist, or a telehealth clinician who is actually contracted with your plan. The well-known national online brands below are mainly cash-pay and should not be confused with an in-network Molina benefit.

The honest part: Ro is the wrong first move for most Molina Medicaid members

Ro does not bill Molina Medicaid, and Medicaid members are not eligible for Ro's Body program.

If using your Molina Medicaid benefits is the priority, Ro cannot be your coverage route, and you should start with Molina's provider directory, your current in-network clinician, and your state's drug list. We'd rather lose the click than send you somewhere that can't do what you need. Find an in-network path instead →

That correction matters for Medicare too. Ro's current rules do not exclude every government-plan member. Some people with Medicare, Medicare Advantage, or TRICARE can join and pay cash, but Ro still does not turn those benefits into Molina coverage.

Where Ro does fit: Molina Marketplace

A Molina Marketplace member has commercial coverage. You have an Evidence of Coverage that may exclude this drug. You may have a prior-authorization or exception process, and most people never use it because it's confusing. Ro's free checker can contact the insurer and report what the plan says about the Wegovy pen before you buy the membership.

Ro also offers FDA-approved Wegovy at the manufacturer cash prices, so if the answer comes back “no coverage,” you are not starting over.

What it costs: get started for $39 for the first month, then as low as $74/month with the annual plan paid upfront or $149/month month to month. Medication is billed separately.

### On a Molina Marketplace plan and tired of fighting this alone? Ro's free checker contacts your insurer and emails you a personalized report on what your plan says about the Wegovy pen. No membership is required to run the check. Check your Wegovy pen coverage free with Ro → (Sponsored. Checks the Wegovy pen, not the tablet. Not a Molina Medicaid billing path — start with a Molina doctor instead.)

If you're paying cash and want to choose your own clinician instead of a membership, Sesame offers per-visit care. (Sponsored.) It does not bill insurance. If you already have a valid prescription, NovoCare avoids adding a telehealth visit fee.

One thing you won't find on this page

We don't mix compounded semaglutide into the Molina coverage answer. This page is about whether insurance covers FDA-approved Wegovy. Compounded semaglutide is not an FDA-approved finished drug, and FDA does not review it for safety, effectiveness, or quality before marketing.

That does not mean every compounded prescription is improper. FDA says compounding may be appropriate when an individual patient's need cannot be met by an FDA-approved drug. It does mean a compounded product should not be presented as generic Wegovy, and you should not assume Molina will reimburse it without a written plan answer.

If a clinic offers you compounded semaglutide when you asked about Wegovy, that's your cue to ask what product you are actually getting, why it is being recommended, which pharmacy makes it, and what happens if the FDA-approved drug is available.

Is Wegovy right for you?

Wegovy is prescription-only and isn't appropriate for everyone. A licensed clinician should review your history, your other medications, the exact Wegovy product, and whether your situation matches an FDA-approved use before you start.

Wegovy carries a boxed warning — the FDA's strongest — about thyroid C-cell tumors seen in rodent studies. It is not for people with a personal or family history of medullary thyroid cancer, or a condition called MEN 2. It is unknown whether Wegovy causes these tumors in humans.

Things your clinician will likely ask about:

• Any personal or family history of medullary thyroid cancer, or MEN 2
• Any history of pancreatitis or gallbladder problems
• Type 2 diabetes, and any history of diabetic eye disease
• Pregnancy, or plans to become pregnant — the label says to stop Wegovy at least 2 months before a planned pregnancy
• Kidney problems or a history of severe dehydration
• Any upcoming surgery or procedure using anesthesia or deep sedation
• Diabetes medications, because of low-blood-sugar risk
• Any other semaglutide or GLP-1 medication you're taking

Read the official Wegovy Prescribing Information and Medication Guide for the exact product, and talk through the warnings with your clinician, before you start or switch.

Your next step, by situation

Frequently asked questions

Does Molina cover Wegovy?

Sometimes, but never automatically. Coverage depends on your plan type, state, exact Wegovy product, current drug list, age, and the reason it is prescribed. Most Molina plans do not cover it for weight loss alone. Molina Medicaid also publishes criteria for cardiovascular risk reduction and MASH, but the state benefit, formulary, and prior authorization still control.

Does Molina Medicaid cover Wegovy for weight loss?

Only through limited state paths. As of August 20, 2026, Mississippi has a confirmed adult and teen PA route. Michigan has a narrow adult route tied to avoiding bariatric surgery. Wisconsin has a weight-management route for ages 12–17, not a routine adult obesity path. Several other Molina states publish direct exclusions, and the rest need a plan-specific written answer.

Which Molina states clearly exclude Wegovy for adult weight loss?

Current official documents clearly close or exclude adult weight-loss use in California, Illinois, Kentucky, Massachusetts, South Carolina, Utah, and Washington. That list does not turn every unlisted state into a yes. Use the state table above and confirm your current Evidence of Coverage and formulary.

Does Molina Marketplace cover Wegovy?

Usually not when the Evidence of Coverage excludes weight-loss drugs. Molina's Marketplace policy, effective May 30, 2026, says that exclusion applies to all Wegovy indications in exclusion states, including cardiovascular risk reduction and MASH. California and New Mexico use separate state rules and separate Molina policies.

Does Molina Medicare cover Wegovy?

Not through normal Part D for weight loss alone. Part D may cover the standard injection or tablet for cardiovascular risk reduction, and the standard injection for MASH, if the formulary and criteria allow it. Separately, the Medicare GLP-1 Bridge offers eligible Part D members covered drugs at $50 per monthly supply through December 31, 2027.

Who cannot use the Medicare GLP-1 Bridge?

The Bridge excludes people with type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH with F2–F3 fibrosis because CMS sends those uses to Part D. A 2026 Part D fill of Zepbound, Mounjaro, Foundayo, Rybelsus, Ozempic, Wegovy, Saxenda, Victoza, or Trulicity also makes you ineligible for the Bridge in 2026.

Does prior authorization mean Wegovy is covered?

No. A prior-authorization form proves a review process exists. It does not prove your product and intended use are a covered benefit. Ask first whether the use is covered or excluded, then whether the exact product is on the drug list, then what paperwork applies.

Why was my Wegovy denied by Molina?

The common reasons are a benefit exclusion, a non-formulary product, missing prior authorization records, or criteria the submitted record did not meet. Get the denial in writing. The exact wording determines whether the problem is fixable paperwork, the wrong product, a missing diagnosis, or a true plan exclusion.

How long do I have to appeal a Molina Medicaid denial?

Federal rules give you 60 calendar days from the adverse-benefit notice to file the Molina appeal. Molina generally has no more than 30 days for a standard appeal or 72 hours for an expedited appeal. If Molina denies again, your state sets the State Fair Hearing deadline between 90 and 120 days after the resolution notice.

Can Molina keep paying while I appeal?

Possibly, when an active Medicaid authorization is being terminated, suspended, or reduced and you request continuation on time. The request must generally be made by the later of 10 days after the notice or the proposed effective date. If the authorization simply expires, the federal continuation rule does not extend it.

Can I get Wegovy if I'm on Molina Medicaid and under 21?

Possibly. EPSDT requires an individual medical-necessity review of Medicaid-coverable treatment for members under 21, even when the ordinary adult benefit excludes the same service. That is not automatic approval. The standard Wegovy injection is FDA-approved for obesity beginning at age 12, while the tablets and Wegovy HD are adult-only.

Does Molina cover the Wegovy pill?

It depends on your plan, state, drug list, and prescribed reason. The tablets are FDA-approved for adult weight management and adult cardiovascular risk reduction, but not MASH. Molina's national Medicaid criteria include a tablet cardiovascular path and a state/plan-specific weight-management path.

Does Molina cover Wegovy HD?

Only through an adult weight-management benefit that is actually open under your state and plan. Wegovy HD 7.2 mg is FDA-approved for adult weight management after 2.4 mg is tolerated and more weight reduction is indicated. It is not FDA-approved for cardiovascular risk reduction or MASH.

How long does Molina take to approve a prior authorization?

There is no single five-day answer for every Molina plan and state. Use the timeframe in your Evidence of Coverage, member handbook, or PA notice. For a Medicaid appeal after a denial, federal rules cap the standard appeal at 30 calendar days and the expedited appeal at 72 hours. A California audit found 15 of 26 sampled routine medical PAs were decided one to three working days later than that plan's five-working-day standard.

Is ConnectiCare the same as Molina?

ConnectiCare is listed as a Molina affiliated company, as are Senior Whole Health and Central Health Plan of California. That tells you the corporate family, not the final coverage answer. Your exact plan's Evidence of Coverage, drug list, state rules, and line of business still control.

Can I pay cash for Wegovy if I have Medicaid or Medicare?

Yes, under Novo's current self-pay terms. You must buy it outside insurance, and the purchase does not count toward your plan deductible or out-of-pocket limit. Government-program members cannot use the commercial copay offer.

Can I use the $25 Wegovy savings card with Molina?

Only if your Molina plan counts as qualifying commercial coverage and covers Wegovy, and you meet the other offer terms. The covered-drug copay offer is capped at $100 for a one-month fill. If Molina excludes Wegovy, use the manufacturer not-covered/self-pay route instead. Medicaid, Medicare, VA, DoD, TRICARE, and similar government-program members cannot use the commercial copay offer, but may still qualify for the separate self-pay price.

What if Molina stopped covering Wegovy after I already started?

Find the denial notice date, proposed stop date, and authorization end date immediately. If Molina cuts an active Medicaid authorization, you may be able to request continued benefits while you appeal. If the authorization simply expires, the federal continuation protection does not extend the expired period. You still generally have 60 days to file the Molina appeal.

Can my doctor change the diagnosis so Molina covers it?

Your clinician should document every diagnosis that is actually supported by your medical record and correct real coding errors. Nobody should enter an inaccurate diagnosis to force a coverage result. The right path depends on the condition you actually have.

Can my regular doctor prescribe Wegovy?

A properly licensed prescriber may prescribe Wegovy when it is medically appropriate and allowed by state law. Coverage is a separate question. For Molina's cardiovascular and MASH Medicaid paths, the policy asks for cardiologist or liver-specialist involvement, with special consideration when timely specialist access is not reasonably available.

Is compounded semaglutide the same as Wegovy?

No. Wegovy is an FDA-approved finished drug. Compounded semaglutide is not FDA-approved, and FDA does not review it for safety, effectiveness, or quality before marketing. Compounding may be appropriate when an individual patient's need cannot be met by an FDA-approved drug, but it should not be presented as generic Wegovy or mixed into a Wegovy insurance-coverage answer.

Still not sure which GLP-1 path is right for you?

Take our free 60-second matching quiz →

Answer a few questions about your card, state, age, prescribed reason, preferred product, and budget. We'll point you to the most realistic next step — Molina coverage, an EPSDT request, a Medicaid appeal, the Medicare GLP-1 Bridge, a free commercial coverage check, in-network care, or the manufacturer-direct cash path.

Sources

Last verified August 20, 2026. Coverage rules, prices, formularies, and program terms change. Re-check the current source before acting.

1. Molina Healthcare — Medicaid clinical criteria: Wegovy (semaglutide), policy C27635-A, current effective date May 30, 2026.
2. Molina Healthcare — Marketplace policy: Wegovy (semaglutide), policy C27682-A, current effective date May 30, 2026.
3. FDA: Wegovy Prescribing Information, revised June 2026.
4. Molina Healthcare: Affiliated Health Plans List as of January 30, 2026.
5. Mississippi Division of Medicaid: Anti-obesity select-agents PA criteria, effective July 1, 2026.
6. Michigan MDHHS: Letter L 25-73, Update of Pharmacy Drug Coverage for Treatment of Obesity.
7. Wisconsin ForwardHealth: Current Wegovy injection and tablet clinical criteria.
8. California DHCS: State Plan Amendment 25-0029 and GLP-1 coverage-change materials.
9. MassHealth: Pharmacy Facts 235 and Pharmacy Facts 276.
10. Molina / state pharmacy materials: Illinois Medicaid formulary page, Kentucky GLP-1 benefit notice, South Carolina July 2026 Comprehensive Drug List, Texas Medicaid/CHIP PA criteria guide, updated April 2026, Utah Medicaid formulary page, and Washington Medicaid formulary page.
11. KFF: Medicaid Coverage of and Spending on GLP-1s, January 2026.
12. CMS: EPSDT benefit requirements.
13. CMS: Medicare GLP-1 Bridge information for providers, Part D plans, and pharmacies.
14. Electronic Code of Federal Regulations: 42 CFR Part 438, Subpart F and 42 CFR 431.244.
15. California DHCS: Medical Audit of Molina Healthcare of California, 2023–24 audit period.
16. California Department of Managed Health Care: Independent Medical Review information and Help Center results.
17. MassHealth Board of Hearings: Appeal decision 2514230.
18. NovoCare: Current Wegovy pricing page, full price guide, and savings/self-pay terms.
19. NovoCare Pharmacy: Current pharmacy terms and covered products.
20. Ro: GLP-1 Insurance Coverage Checker, Body membership pricing, and government-plan eligibility information.
21. Sesame: Terms of Service.
22. Hims & Hers: Wegovy pill and pen availability announcement and current weight-loss program pages.
23. FDA: Concerns with unapproved GLP-1 drugs used for weight loss.
24. Social Security Act: Section 1927(d)(2), drug categories states may exclude when used for listed purposes.
25. Molina Healthcare: 2025 Form 10-K and first-quarter 2026 Form 10-Q — Nevada Medicaid contract effective January 1, 2026; Virginia Medicaid contract expired June 30, 2025.

This guide is general information, not medical, legal, or insurance advice. Coverage and pricing vary by plan and state and change frequently. Confirm current details with your plan, your clinician, and the official sources before making decisions.